| Published Application/Species/Sample/Dilution | Reference |
|---|
- western blot; human; 1:1000; loading ...; fig 3c
| Chung H, Zou X, Bajar B, Brand V, Huo Y, Alcudia J, et al. A compact synthetic pathway rewires cancer signaling to therapeutic effector release. Science. 2019;364: pubmed publisher |
- immunohistochemistry - paraffin section; mouse; loading ...; fig s5a
| Park J, Kim I, Choi J, Lim H, Shin J, Kim Y, et al. AHNAK Loss in Mice Promotes Type II Pneumocyte Hyperplasia and Lung Tumor Development. Mol Cancer Res. 2018;16:1287-1298 pubmed publisher |
- western blot; human; loading ...; fig 1a
| Baumann C, Ullrich A, Torka R. GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance. Mol Oncol. 2017;11:1430-1447 pubmed publisher |
- western blot; human; loading ...; fig 1b
| Vaishnavi A, Schubert L, Rix U, Marek L, Le A, Keysar S, et al. EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res. 2017;77:3551-3563 pubmed publisher |
- western blot; human; loading ...; fig 2
| Xiao Z, Gaertner S, Morresi Hauf A, Genzel R, Duell T, Ullrich A, et al. Metformin Triggers Autophagy to Attenuate Drug-Induced Apoptosis in NSCLC Cells, with Minor Effects on Tumors of Diabetic Patients. Neoplasia. 2017;19:385-395 pubmed publisher |
- western blot; human; loading ...; fig 2a
- western blot; mouse; loading ...; fig 2b
| Shizu R, Osabe M, Perera L, Moore R, Sueyoshi T, Negishi M. Phosphorylated Nuclear Receptor CAR Forms a Homodimer To Repress Its Constitutive Activity for Ligand Activation. Mol Cell Biol. 2017;37: pubmed publisher |
- western blot; human; loading ...
| Cao H, Yu S, Chen D, Jing C, Wang Z, Ma R, et al. Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR-TKI treatment. FEBS Open Bio. 2017;7:35-43 pubmed publisher |
- western blot; mouse; loading ...; fig 8b
| Lee H, Khan S, Khaliqdina S, Altintas M, Grahammer F, Zhao J, et al. Absence of miR-146a in Podocytes Increases Risk of Diabetic Glomerulopathy via Up-regulation of ErbB4 and Notch-1. J Biol Chem. 2017;292:732-747 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 6a
| Carino A, Graziosi L, D Amore C, Cipriani S, Marchianò S, Marino E, et al. The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines. Oncotarget. 2016;7:61021-61035 pubmed publisher |
- western blot; human; 1:1000; fig s2
| Deblois G, Smith H, Tam I, Gravel S, Caron M, Savage P, et al. ERR? mediates metabolic adaptations driving lapatinib resistance in breast cancer. Nat Commun. 2016;7:12156 pubmed publisher |
| Jadwin J, Oh D, Curran T, Ogiue Ikeda M, Jia L, White F, et al. Time-resolved multimodal analysis of Src Homology 2 (SH2) domain binding in signaling by receptor tyrosine kinases. elife. 2016;5:e11835 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig s3j
| Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, et al. The LINK-A lncRNA activates normoxic HIF1? signalling in triple-negative breast cancer. Nat Cell Biol. 2016;18:213-24 pubmed publisher |
- western blot; human; fig 3
| Mehner C, Oberg A, Kalli K, Nassar A, Hockla A, Pendlebury D, et al. Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. Oncotarget. 2015;6:35737-54 pubmed publisher |
- western blot; human; fig 5
| Yang L, Li Y, Bhattacharya A, Zhang Y. Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant. EBioMedicine. 2015;2:396-405 pubmed |
- western blot; human; fig s3
| Ma S, Yin N, Qi X, Pfister S, Zhang M, Ma R, et al. Tyrosine dephosphorylation enhances the therapeutic target activity of epidermal growth factor receptor (EGFR) by disrupting its interaction with estrogen receptor (ER). Oncotarget. 2015;6:13320-33 pubmed |
| Rayavarapu R, Heiden B, Pagani N, Shaw M, Shuff S, Zhang S, et al. The role of multicellular aggregation in the survival of ErbB2-positive breast cancer cells during extracellular matrix detachment. J Biol Chem. 2015;290:8722-33 pubmed publisher |
- western blot; human; loading ...; fig 1a
| Greenall S, Donoghue J, van Sinderen M, Dubljevic V, Budiman S, Devlin M, et al. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene. 2015;34:5277-87 pubmed publisher |
| Ebelt N, Kaoud T, Edupuganti R, Van Ravenstein S, Dalby K, Van Den Berg C. A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib. Oncotarget. 2017;8:104894-104912 pubmed publisher |
| Saloura V, Vougiouklakis T, Zewde M, Deng X, Kiyotani K, Park J, et al. WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer. Sci Rep. 2017;7:40664 pubmed publisher |
| Lindberg O, McKinney A, Engler J, Koshkakaryan G, Gong H, Robinson A, et al. GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity. Oncotarget. 2016;7:79101-79116 pubmed publisher |
| Qu X, Sandmann T, Frierson H, Fu L, Fuentes E, Walter K, et al. Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter. Oncogene. 2016;35:6403-6415 pubmed publisher |
| Steinway S, Dang H, You H, Rountree C, Ding W. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma. PLoS ONE. 2015;10:e0128159 pubmed publisher |
| Xiao Z, Sperl B, Ullrich A, Knyazev P. Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status. Oncotarget. 2014;5:12877-90 pubmed |
| Algars A, Avoranta T, Osterlund P, Lintunen M, Sundström J, Jokilehto T, et al. Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy. PLoS ONE. 2014;9:e99590 pubmed publisher |
| Wang F, Wang S, Wang Z, Duan J, An T, Zhao J, et al. Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR. J Exp Clin Cancer Res. 2012;31:65 pubmed publisher |
| Yip W, Seow H. Activation of phosphatidylinositol 3-kinase/Akt signaling by EGF downregulates membranous E-cadherin and ?-catenin and enhances invasion in nasopharyngeal carcinoma cells. Cancer Lett. 2012;318:162-72 pubmed publisher |
| Sakuma Y, Yamazaki Y, Nakamura Y, Yoshihara M, Matsukuma S, Nakayama H, et al. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Lab Invest. 2012;92:371-83 pubmed publisher |
| Benedettini E, Sholl L, Peyton M, Reilly J, Ware C, Davis L, et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol. 2010;177:415-23 pubmed publisher |
| Frogne T, Laenkholm A, Lyng M, Henriksen K, Lykkesfeldt A. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res. 2009;11:R11 pubmed publisher |
